The effects of leukotriene receptor antagonist montelukast on histological, radiological and densitometric parameters of fracture healing

被引:0
作者
Cakici, Husamettin [1 ]
Hapa, Onur [3 ]
Gideroglu, Kaan [4 ]
Ozturan, Kutay [1 ]
Guven, Melih [1 ]
Yuksel, Halil Yalcin [5 ]
Yilmaz, Fahri [2 ]
机构
[1] Abant Izzet Baysal Univ, Tip Fak, Ortopedi & Travmatol Anabilim Dali, TR-14280 Golkoy, Bolu, Turkey
[2] Abant Izzet Baysal Univ, Tip Fak, Dept Pathol, TR-14280 Golkoy, Bolu, Turkey
[3] Mustafa Kemal Univ, Fac Med, Dept Orthoped & Traumatol, Antakya, Turkey
[4] Dr Lutfi Kirdar Training & Res Hosp, Dept Plast & Reconstruct Surg, Istanbul, Turkey
[5] Ankara Numune Training & Res Hosp, Dept Orthoped & Traumatol 3, Ankara, Turkey
来源
EKLEM HASTALIKLARI VE CERRAHISI-JOINT DISEASES AND RELATED SURGERY | 2011年 / 22卷 / 01期
关键词
Experimental study; fracture healing; leukotriene-receptor antagonist; montelukast; ISCHEMIA/REPERFUSION INJURY; RATS; INDOMETHACIN; CELECOXIB; PROTECTS; REPAIR;
D O I
暂无
中图分类号
R826.8 [整形外科学]; R782.2 [口腔颌面部整形外科学]; R726.2 [小儿整形外科学]; R62 [整形外科学(修复外科学)];
学科分类号
摘要
Objectives: In this study we evaluated the effects of montelukast, a leukotriene-receptor antagonist, on fracture healing, and investigated the hypothesis that enhanced fracture healing would be observed with montelukast in a rat tibia fracture model. Materials and methods: Sixty adult (6 months old) female Wistar albino rats (mean weight 220 g, range 210-270 g) were randomly divided into two groups: a montelukast group (n=30) and a control group (n=30). Closed tibia fractures were created and fixed by intramedullary Kirschner wire. The rats were sacrificed three and six weeks after the fractures. Radiological and histological evaluations were performed, and bone mineral density was measured. Results: Three rats died in the montelukast group, whereas only one died in the control group during the study. Initial weight and weight gain at the 3(rd) and 6(th) weeks were not significantly different between the groups (p>0.05). Bone mineral densities in the control and study groups were 0.13 +/- 0.009 gr/cm(2), and 0.13 +/- 0.01 gr/cm(2) at week three and 0.16 +/- 0.02 gr/cm(2), and 0.13 +/- 0.01 gr/cm(2) at week six, respectively. Histopathological scores in the control and study groups were 3.42 +/- 0.6, and 3.0 +/- 0.0 at week three and 3.5 +/- 0.5, and 3.4 +/- 0.8 at week six, respectively. Radiological scores in the control and study groups were 1.19 +/- 0.6, and 1.0 +/- 0.6 at week three and 3.0 +/- 0.8, and 2.9 +/- 0.9 at week six, respectively. There were no significant differences between the two groups in any parameters evaluated at either time interval (p>0.05). Conclusion: Our study failed to show a possible positive effect of leukotriene receptor inhibition on fracture healing at the 3(rd) and 6(th) postoperative weeks.
引用
收藏
页码:43 / 47
页数:5
相关论文
共 50 条
  • [21] Montelukast, a leukotriene receptor antagonist, reduces the concentration of leukotrienes in the respiratory tract of children with persistent asthma
    Volovitz, B
    Tabachnik, E
    Nussinovitch, M
    Shtaif, B
    Blau, H
    Gil-Ad, I
    Weizman, A
    Varsano, I
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1999, 104 (06) : 1162 - 1167
  • [22] Effect of montelukast, a once-daily leukotriene receptor antagonist, on peak expiratory flow variability
    Zhang, J
    Yu, C
    Noonan, G
    Reiss, TF
    CLINICAL THERAPEUTICS, 2002, 24 (04) : 574 - 582
  • [23] Anti-inflammatory Properties of Montelukast, a Leukotriene Receptor Antagonist in Patients With Asthma and Nasal Polyposis
    Schaeper, C.
    Noga, O.
    Koch, B.
    Ewert, R.
    Felix, S. B.
    Glaeser, S.
    Kunkel, G.
    Gustavus, B.
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY, 2011, 21 (01) : 51 - 58
  • [24] Effects of oral cysteine leukotriene receptor antagonist-montelukast on adenoid lymphoid tissue: a histopathological study under light microscope
    Wang, Zhengying
    Wu, Xiuling
    Liu, Jinghong
    Wang, Yu
    Zhang, Yue
    Wu, Yan
    Kang, Yingxue
    Zhang, Ronghai
    Li, Jin
    Liu, Delong
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [25] Radioprotective effects of montelukast, a selective leukotriene CysLT1 receptor antagonist, against nephrotoxicity induced by gamma radiation in mice
    Hormati, Ahmad
    Ahmadpour, Sajjad
    Afkhami Ardekani, Mahdieh
    Khodadust, Fatemeh
    Refahi, Soheila
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 2020, 34 (06)
  • [26] Cysteine Leukotriene Receptor Antagonist-Montelukast-Treatment Improves Experimental Abdominal Aortic Aneurysms in Mice
    Li, Kexin
    Li, Meng
    Wei, Panpan
    Tian, Kangli
    Liu, Haole
    Fu, Weilai
    Hou, Haiwen
    Chen, Yajie
    Xu, Baohui
    Li, Yankui
    Zhao, Sihai
    CARDIOVASCULAR THERAPEUTICS, 2024, 2024 : 8826287
  • [27] Efficacy of montelukast, a leukotriene receptor antagonist, for the treatment of dysmenorrhea: A prospective, double-blind, randomized, placebo-controlled study
    Fujiwara, Hiroyuki
    Konno, Ryo
    Netsu, Sachiho
    Odagiri, Kohei
    Taneichi, Akiyo
    Takamizawa, Satoshi
    Ohwada, Michitaka
    Suzuki, Mitsuaki
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2010, 148 (02) : 195 - 198
  • [28] A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist
    Altman, LC
    Munk, Z
    Seltzer, J
    Noonan, N
    Shingo, S
    Zhang, J
    Reiss, TF
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1998, 102 (01) : 50 - 56
  • [29] Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood–brain barrier
    Li Zhou
    Xiaomin Sun
    Yong Shi
    Junpeng Liu
    Guohui Luan
    Yanwen Yang
    Inflammopharmacology, 2019, 27 : 933 - 940
  • [30] Montelukast, a cysteinyl leukotriene receptor antagonist, inhibits the growth of chronic myeloid leukemia cells through apoptosis
    Zovko, Ana
    Yektaei-Karin, Elham
    Salamon, Daniel
    Nilsson, Anders
    Wallvik, Jonas
    Stenke, Leif
    ONCOLOGY REPORTS, 2018, 40 (02) : 902 - 908